Oct 8 (Reuters) - China's WuXi AppTec
said on Tuesday it was assessing options for continuing its cell and gene therapy manufacturing business, WuXi Advanced Therapies, but it has not entered any binding deals regarding the operations.
"There is uncertainty as to whether the company will eventually decide to dispose WuXi ATU, or take other options to retain WuXi ATU and execute other options so that such business can continue to operate," it said in an exchange filing.
(Reporting by Himanshi Akhand in Bengaluru; Editing by Alan Barona)
((Himanshi.Akhand@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。